Mayuresh Joshi Reveals Investment Focus: Capitalizing on Pharma, Energy, and Mid-Sized Banks
Indian equity markets are witnessing a notable rebound, bolstered by a reduction in geopolitical tensions in West Asia, according to Mayuresh Joshi, Head-Equity Marketsmith India. This shift has catalyzed a clearer earnings trajectory for the latter half of the year, fostering an environment of cautious optimism. Joshi acknowledges that the near-term landscape may remain tumultuous, particularly in the first quarter, which is likely to be characterized by persistently challenging conditions stemming from supply chain disruptions, input cost inflation, and softening demand across various sectors. However, he encourages investors to maintain their focus on the long-term potential despite the anticipated difficulties in Q1, including the influence of El Niño on agricultural outputs and rural spending.
In terms of sectoral positioning, Joshi highlights pharmaceuticals, domestic engineering, and the power and utilities segments as key areas poised for growth in the second half of the year. Within the pharma space, he expresses particular confidence in the contract development and manufacturing organization (CDMO) and contract servicing model (CSM), identifying Sai Life Sciences as a standout due to its robust growth story and capacity expansions. Additionally, Aether Industries has been flagged for its significant revenue contributions stemming from its specialized chemical segments and promising new product launches. On the healthcare front, Joshi continues to favor Max Healthcare and Apollo Hospitals, citing their strategic asset-light expansion into tier II and III cities, despite the looming risks of government pricing caps and insurance dynamics that could impact revenues.
The banking sector presents a nuanced picture as well. Joshi has strategically reduced his positions in public sector banks following their strong performance. His current focus has shifted to mid-sized private banks, such as Karur Vysya Bank, which he praises for its strong financial metrics and diversified loan portfolio. He remains cautious regarding larger private sector banks, as variables like deposit growth and net interest margins will dictate re-entry opportunities. Notably, while CSB Bank may face short-term pressures due to potential shareholder changes, its fundamental growth story remains solid in Joshi’s view, sustaining attention from savvy investors.
Overall, as West Asian risks abate and domestic macroeconomic indicators remain supportive, Joshi’s outlook for the market suggests gradual improvement. The initial challenges of Q1 could serve as a setup for future gains, particularly in quality sectors such as pharmaceuticals, healthcare, engineering, and select financials. Investors are encouraged to look beyond immediate obstacles and position themselves strategically to capitalize on upcoming growth opportunities.
Source: The Economic Times
(Expert Note: This report was prepared by the Wealthova team.)